Syntara on advancing first-in-class Myelofibrosis therapy with multiple pipeline opportunities
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Syntara Ltd (ASX:SNT) chief Gary Phillips for a high-level overview on the biotech company’s objectives in treating blood cancers and fibrosis, what underpins its value proposition, an...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| NFN | Ann: 2026 AGM Results | 04/02/26 | 0 | 117 | |||
|
|||||||
| NFN | Ann: 2026 AGM Speeches and Proxy Vote Summary | 04/02/26 | 0 | 103 | |||
|
|||||||
| NFN | Ann: Notice of Annual General Meeting/Proxy Form | 12/12/25 | 0 | 164 | |||
|
|||||||
| NFN | Ann: Appendix 4G | 12/12/25 | 0 | 113 | |||
|
|||||||
| NFN | Ann: FY25 ESG Impact Statement | 12/12/25 | 0 | 153 | |||
|
|||||||
| NFN | Ann: 2025 Climate Statement | 12/12/25 | 0 | 102 | |||
|
|||||||
| NFN | Ann: Annual Report to shareholders | 12/12/25 | 0 | 176 | |||
|
|||||||
| NFN | Ann: Credit rating update | 10/12/25 | 0 | 115 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
ASX News